Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shen zhi ling oral liquid for amnestic mild cognitive impairment and mild Alzheimer's disease
ChiCTR-IPR-15007499Phase 4Recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Nov 2015
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Shen zhi ling oral liquid in amnestic mild cognitive impairment (MCI) and Alzheimer's disease (AD) (4 arms), sponsored by Beijing An Zhen Hospital. Primary endpoints: Mini-Mental State Examination and Alzheimer's Disease Assessment Scale - Cognitive Subscale. Started Nov 2015; status: recruiting.
02
Drugs
Shen zhi ling oral liquid
03
Conditions
amnestic mild cognitive impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR-IPR-15007499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15007499.